Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

The medicinal properties of marijuana have been recognized for centuries, but clinical and societal acceptance of this drug of abuse as a potential therapeutic agent remains fiercely debated. An attractive alternative to marijuana-based therapeutics would be to target the molecular pathways that mediate the effects of this drug. To date, these neural signaling pathways have been shown to comprise a cannabinoid receptor (CB 1 ) that binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous CB 1 ligand anandamide. Although anandamide binds and activates the CB 1 receptor in vitro , this compound induces only weak and transient cannabinoid behavioral effects in vivo , possibly a result of its rapid catabolism. Here we show that mice lacking the enzyme fatty acid amide hydrolase (FAAH −/− ) are severely impaired in their ability to degrade anandamide and when treated with this compound, exhibit an array of intense CB 1 -dependent behavioral responses, including hypomotility, analgesia, catalepsy, and hypothermia. FAAH −/− -mice possess 15-fold augmented endogenous brain levels of anandamide and display reduced pain sensation that is reversed by the CB 1 antagonist SR141716A. Collectively, these results indicate that FAAH is a key regulator of anandamide signaling in vivo , setting an endogenous cannabinoid tone that modulates pain perception. FAAH may therefore represent an attractive pharmaceutical target for the treatment of pain and neuropsychiatric disorders.

Bibliography

Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences, 98(16), 9371–9376.

Authors 7
  1. Benjamin F. Cravatt (first)
  2. Kristin Demarest (additional)
  3. Matthew P. Patricelli (additional)
  4. Michael H. Bracey (additional)
  5. Dan K. Giang (additional)
  6. Billy R. Martin (additional)
  7. Aron H. Lichtman (additional)
References 42 Referenced 1,094
  1. 10.1016/S1367-5931(99)80062-3
  2. 10.1016/S0165-6147(00)01482-6
  3. 10.1016/S0024-3205(99)00281-7
  4. R Mechoulam Cannabinoids as Therapeutic Agents (CRC, Boca Raton, FL), pp. 1–19 (1986). / Cannabinoids as Therapeutic Agents by Mechoulam R (1986)
  5. 10.1016/S0163-7258(97)82001-3
  6. 10.1126/science.1470919
  7. 10.1073/pnas.90.16.7656
  8. 10.1073/pnas.96.21.12198
  9. 10.1016/0091-3057(93)90230-Q
  10. 10.1016/0014-2999(93)90468-W
  11. P B Smith, D R Compton, S P Welch, R K Razdan, R Mechoulam, B R Martin J Pharmacol Exp Ther 270, 219–227 (1994). / J Pharmacol Exp Ther by Smith P B (1994)
  12. 10.1016/0006-2952(94)90134-1
  13. 10.1007/BF00169393
  14. I B Adams, D R Compton, B R Martin J Pharmacol Exp Ther 284, 1209–1217 (1998). / J Pharmacol Exp Ther by Adams I B (1998)
  15. 10.1097/00008877-199905000-00009
  16. 10.1046/j.1471-4159.2000.0752434.x
  17. 10.1038/22761
  18. 10.1038/376590a0
  19. 10.1016/0006-2952(95)00109-D
  20. 10.1006/bbrc.1995.2437
  21. K A Willoughby, S F Moore, B R Martin, E F Ellis J Pharmacol Exp Ther 282, 243–247 (1997). / J Pharmacol Exp Ther by Willoughby K A (1997)
  22. 10.1038/384083a0
  23. 10.1126/science.277.5329.1094
  24. 10.1016/S0014-5793(99)00820-0
  25. 10.1073/pnas.94.6.2238
  26. 10.1021/bi981733n
  27. 10.1021/bi990637z
  28. 10.1016/0006-2952(93)90486-G
  29. 10.1016/0014-5793(95)01311-3
  30. 10.1074/jbc.270.40.23823
  31. 10.1074/jbc.270.11.6030
  32. 10.1038/28393
  33. 10.1126/science.7770779
  34. 10.1098/rspb.1998.0543
  35. 10.1016/S0304-3940(98)00700-9
  36. 10.1016/0014-5793(94)00773-X
  37. 10.1038/32897
  38. 10.1038/372686a0
  39. 10.1073/pnas.96.24.14136
  40. 10.1038/35057062
  41. 10.1126/science.1058040
  42. 10.1073/pnas.97.10.5044
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 6:37 a.m.)
Deposited 3 years, 4 months ago (April 12, 2022, 9:35 p.m.)
Indexed 2 days, 18 hours ago (Aug. 30, 2025, 1 p.m.)
Issued 24 years, 1 month ago (July 24, 2001)
Published 24 years, 1 month ago (July 24, 2001)
Published Online 24 years, 1 month ago (July 24, 2001)
Published Print 24 years, 1 month ago (July 31, 2001)
Funders 0

None

@article{Cravatt_2001, title={Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase}, volume={98}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.161191698}, DOI={10.1073/pnas.161191698}, number={16}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Cravatt, Benjamin F. and Demarest, Kristin and Patricelli, Matthew P. and Bracey, Michael H. and Giang, Dan K. and Martin, Billy R. and Lichtman, Aron H.}, year={2001}, month=jul, pages={9371–9376} }